SIBO (small intestinal bacterial overgrowth) is excess bacterial colonization of the small intestine, an area that normally has low bacterial density (fewer than 103 colony-forming units per mL, versus 109-1012 CFU/mL in the colon). It produces bloating, gas, and altered bowel habits, and drives Endotoxin absorption and Inflammation through the same leaky-gut mechanisms discussed on the Gut page.

Prevalence and comorbidity

[edit]

SIBO is common and frequently missed, but the prevalence figures in wellness/social-media claims about it often run higher than what current meta-analyses actually find:

  • IBS: An older single-center study found 78% of 202 IBS patients tested positive via lactulose breath testing.[1] Lactulose breath testing is prone to false positives from rapid gut transit, and a larger 2022 meta-analysis of over 6,700 IBS patients across 36 studies found a lower pooled rate: 49% by lactulose testing, 19% by the more specific glucose test.[2] Real overlap either way, just not as high as 78% by the better test.
  • PPI use: A 2025 meta-analysis of 29 studies (3,682 PPI patients, 2,907 controls) found a pooled SIBO prevalence of 36.8% in PPI users versus 19.9% in controls (OR 2.14), with risk rising the longer PPI treatment continued.[3] Real, roughly doubled risk, not "at least half."
  • Hypothyroidism: A 2026 study combining duodenal microbiome sampling with a 10-year outcomes database found SIBO in 32.65% of hypothyroid subjects versus 15.17% of controls, a roughly 2.2-fold increased risk that was largely reversed in patients taking levothyroxine.[4] Real association tying back to the MMC mechanism below, closer to a third of patients than half. A separate, larger retrospective cohort (1,809 patients) found levothyroxine therapy itself was a stronger SIBO predictor than hypothyroidism, and unable to reverse hypothyroidism's effect on SIBO risk.[5] Levothyroxine is T4 alone; as noted on Thyroxine, T4 requires liver conversion to T3 that's often impaired, so T4 monotherapy commonly fails to correct tissue-level hypothyroidism even when it normalizes TSH, which would explain why it doesn't reliably fix SIBO either.

SIBO also shows up as a comorbidity across a range of other conditions studied independently of IBS/PPI/thyroid status: Alzheimer's disease,[6] Parkinson's disease,[7] systemic sclerosis,[8] and pancreatic/cholangiocarcinoma.[9] These associational studies don't establish that SIBO causes those diseases, only that it co-occurs at elevated rates, but they support treating SIBO as a systemic condition rather than a purely digestive one.

Symptoms

[edit]

Beyond the classic digestive symptoms (bloating, gas 30-90 minutes post-meal, altered bowel movements, abdominal pain, acid reflux), SIBO's systemic effects can include nutrient deficiencies (bacterial competition for vitamin B12 is a recognized mechanism, see Vitamin B12), new food intolerances, histamine intolerance/MCAS, and worsening of existing autoimmune conditions, on top of the Chronic fatigue and brain fog that follow from the Endotoxin/Inflammation burden described on the Gut page.

Cause

[edit]

The small intestine is normally kept clear of bacterial overgrowth by the migrating motor complex (MMC), a cyclic wave of muscular contraction that sweeps residual food and bacteria toward the colon between meals. Anything that slows motility or interrupts the MMC (hypothyroidism, chronic stress, opioids, prior gut infection, structural narrowing) allows bacteria to accumulate and ferment food in the small intestine instead of the colon.

Migrating motor complex (MMC)

[edit]

The MMC runs in roughly 90-120 minute cycles during fasting and is suppressed by eating. Frequent snacking or grazing prevents the MMC from completing its sweeping phase, one reason meal spacing is emphasized for gut health on this wiki, see Roadmap/02 - Self diagnosis & markers.

Types

[edit]
  • Hydrogen-dominant SIBO: excess fermentation gas, often with diarrhea.
  • Methane-dominant SIBO (intestinal methanogen overgrowth, IMO): archaea convert hydrogen to methane, associated with constipation.
  • Hydrogen sulfide SIBO: less commonly tested, associated with sulfur-smelling gas and visceral hypersensitivity.

Treatment

[edit]

Rifaximin is a gut-selective, minimally absorbed antibiotic commonly used for hydrogen-dominant SIBO. Methane-dominant cases are often treated with rifaximin combined with a second antibiotic (commonly neomycin). Prokinetics are used after antibiotic treatment to restore MMC cycling and reduce relapse.

See also

[edit]
  1. ↑ Pimentel M, Chow EJ, Lin HC. "Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome," Am J Gastroenterol. 2000;95(12):3503-3506. PMID 11151884.
  2. ↑ Poon D, Law GR, Major G, Andreyev HJN. "A systematic review and meta-analysis on the prevalence of non-malignant, organic gastrointestinal disorders misdiagnosed as irritable bowel syndrome," Sci Rep. 2022;12(1):1949. PMID 35121775.
  3. ↑ Khurmatullina AR, Andreev DN, Kucheryavyy YA, et al. "The Duration of Proton Pump Inhibitor Therapy and the Risk of Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-Analysis," J Clin Med. 2025;14(13):4702. PMID 40649078.
  4. ↑ "Relationship Between Hypothyroidism, Risk of Small Intestinal Bacterial Overgrowth, and Duodenal Microbiome Alterations," J Clin Endocrinol Metab. 2026;111(3):707-720. PMID 40908532.
  5. ↑ Brechmann T, Sperlbaum A, Schmiegel W. "Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: Results of a retrospective cohort study," World J Gastroenterol. 2017;23(5):842-852. PMID 28223728.
  6. ↑ Kowalski K, Mulak A. "Small intestinal bacterial overgrowth in Alzheimer's disease," J Neural Transm. 2022;129(1):75-83. PMID 34797427.
  7. ↑ Li X, Feng X, Jiang Z, Jiang Z. "Association of small intestinal bacterial overgrowth with Parkinson's disease: a systematic review and meta-analysis," Gut Pathog. 2021;13(1):25. PMID 33863370.
  8. ↑ Shah A, et al. "Small Intestinal Bacterial Overgrowth Complicating Gastrointestinal Manifestations of Systemic Sclerosis: A Systematic Review and Meta-analysis," J Neurogastroenterol Motil. 2023;29(2):132-144. PMID 37019859.
  9. ↑ Ma Y, et al. "Association between small intestinal bacterial overgrowth and toll-like receptor 4 in patients with pancreatic carcinoma and cholangiocarcinoma," Turk J Gastroenterol. 2019;30(7):630-638. doi:10.5152/tjg.2018.17512.